Gentian Diagnostics (GENT) Q3 2026 earnings summary

Executive summary

• Record Q3 sales of NOK 51.1m, up 22% reported and 30% currency-neutral organically; EBITDA was NOK 13.6m.

• Seven assay development projects and one technology project were active; Europe and the US led quarterly growth.

Financial highlights

• Q3 revenue was NOK 51.1m versus NOK 41.8m; 9M revenue was NOK 144.8m versus NOK 129.9m, up 11% reported and 17% currency-neutral organically.

• Q3 operating profit was NOK 11.4m and net profit NOK 7.3m; 9M operating loss was NOK 10.2m and net loss NOK 8.5m, including a NOK 30.2m non-cash impairment.

• Q3 operating cash flow was NOK 14.9m; 9M operating cash flow was negative NOK 0.9m, mainly reflecting a NOK 17.8m increase in receivables.

• Q3 operating expenses were NOK 21.8m; underlying 9M OPEX rose 4.5%, reflecting higher activity and general cost increases.

Outlook and guidance

• Strong Q4 order intake supports expected full-year 2026 Cystatin C growth; the key IVD partner assay remains on track for Q4 2027 launch.

• Long-term targets are a 55%-60% gross margin and 40% EBITDA margin; new projects target return on capital employed above 20%.

• Pipeline commercialization horizons span 12-36+ months; timing depends on technical progress, partners and regulatory requirements.